Evaluation of the efficacy of cisplatin–etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC
In small-cell lung cancer (SCLC), the role of chemotherapy and radiotherapy is well established. Large-cell neuroendocrine carcinoma (LCNEC) shares several clinicopathological features with SCLC, but its optimal therapy is not defined. We evaluated clinical response and survival outcomes of advanced...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Respiratory Society
2017-03-01
|
| Series: | ERJ Open Research |
| Online Access: | http://openres.ersjournals.com/content/3/1/00128-2016.full |
| _version_ | 1811231496978038784 |
|---|---|
| author | Arsela Prelaj Sara Elena Rebuzzi Gabriella Del Bene Julio Rodrigo Giròn Berrìos Alessandra Emiliani Lucilla De Filippis Alessandra Anna Prete Silvia Pecorari Gaia Manna Carla Ferrara Daniele Rossini Flavia Longo |
| author_facet | Arsela Prelaj Sara Elena Rebuzzi Gabriella Del Bene Julio Rodrigo Giròn Berrìos Alessandra Emiliani Lucilla De Filippis Alessandra Anna Prete Silvia Pecorari Gaia Manna Carla Ferrara Daniele Rossini Flavia Longo |
| author_sort | Arsela Prelaj |
| collection | DOAJ |
| description | In small-cell lung cancer (SCLC), the role of chemotherapy and radiotherapy is well established. Large-cell neuroendocrine carcinoma (LCNEC) shares several clinicopathological features with SCLC, but its optimal therapy is not defined. We evaluated clinical response and survival outcomes of advanced LCNEC treated in first-line therapy compared with SCLC. 72 patients with stage III–IV LCNEC (n=28) and extensive-stage SCLC (ES-SCLC) (n=44) received cisplatin–etoposide with/without thoracic radiotherapy (TRT) and prophylactic cranial irradiation (PCI). Comparing LCNEC with SCLC, we observed similar response rates (64.2% versus 59.1%), disease control rates (82.1% versus 88.6%), progression-free survival (mPFS) (7.4 versus 6.1 months) and overall survival (mOS) (10.4 versus 10.9 months). TRT and PCI in both histologies showed a benefit in mOS (34 versus 7.8 months and 34 versus 8.6 months, both p=0.0001). LCNEC patients receiving TRT showed an improvement in mPFS and mOS (12.5 versus 5 months, p=0.02 and 28.3 versus 5 months, p=0.004), similarly to ES-SCLC. PCI in LCNEC showed an increase in mPFS (20.5 versus 6.4 months, p=0.09) and mOS (33.4 versus 8.6 months, p=0.05), as in ES-SCLC. Advanced LCNEC treated with SCLC first-line therapy has a similar clinical response and survival outcomes to ES-SCLC. |
| first_indexed | 2024-04-12T10:46:21Z |
| format | Article |
| id | doaj.art-fbf069b64a824bdca1f7b358061bc685 |
| institution | Directory Open Access Journal |
| issn | 2312-0541 |
| language | English |
| last_indexed | 2024-04-12T10:46:21Z |
| publishDate | 2017-03-01 |
| publisher | European Respiratory Society |
| record_format | Article |
| series | ERJ Open Research |
| spelling | doaj.art-fbf069b64a824bdca1f7b358061bc6852022-12-22T03:36:26ZengEuropean Respiratory SocietyERJ Open Research2312-05412017-03-013110.1183/23120541.00128-201600128-2016Evaluation of the efficacy of cisplatin–etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNECArsela Prelaj0Sara Elena Rebuzzi1Gabriella Del Bene2Julio Rodrigo Giròn Berrìos3Alessandra Emiliani4Lucilla De Filippis5Alessandra Anna Prete6Silvia Pecorari7Gaia Manna8Carla Ferrara9Daniele Rossini10Flavia Longo11 Dept of Medical Oncology Unit A, Policlinico Umberto I, “Sapienza” University of Rome, Rome, Italy Department of Medical Oncology, IRCCS San Martino IST, Genoa, Italy Dept of Medical Oncology Unit A, Policlinico Umberto I, “Sapienza” University of Rome, Rome, Italy Dept of Medical Oncology Unit A, Policlinico Umberto I, “Sapienza” University of Rome, Rome, Italy Dept of Medical Oncology Unit A, Policlinico Umberto I, “Sapienza” University of Rome, Rome, Italy Dept of Medical Oncology Unit A, Policlinico Umberto I, “Sapienza” University of Rome, Rome, Italy Dept of Medical Oncology Unit A, Policlinico Umberto I, “Sapienza” University of Rome, Rome, Italy Dept of Medical Oncology Unit A, Policlinico Umberto I, “Sapienza” University of Rome, Rome, Italy Dept of Medical Oncology Unit A, Policlinico Umberto I, “Sapienza” University of Rome, Rome, Italy Department of Public Health and Infectious Diseases, “Sapienza” University of Rome, Rome, Italy Polo Oncologico, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy University of Pisa, Pisa, Italy Dept of Medical Oncology Unit A, Policlinico Umberto I, “Sapienza” University of Rome, Rome, Italy In small-cell lung cancer (SCLC), the role of chemotherapy and radiotherapy is well established. Large-cell neuroendocrine carcinoma (LCNEC) shares several clinicopathological features with SCLC, but its optimal therapy is not defined. We evaluated clinical response and survival outcomes of advanced LCNEC treated in first-line therapy compared with SCLC. 72 patients with stage III–IV LCNEC (n=28) and extensive-stage SCLC (ES-SCLC) (n=44) received cisplatin–etoposide with/without thoracic radiotherapy (TRT) and prophylactic cranial irradiation (PCI). Comparing LCNEC with SCLC, we observed similar response rates (64.2% versus 59.1%), disease control rates (82.1% versus 88.6%), progression-free survival (mPFS) (7.4 versus 6.1 months) and overall survival (mOS) (10.4 versus 10.9 months). TRT and PCI in both histologies showed a benefit in mOS (34 versus 7.8 months and 34 versus 8.6 months, both p=0.0001). LCNEC patients receiving TRT showed an improvement in mPFS and mOS (12.5 versus 5 months, p=0.02 and 28.3 versus 5 months, p=0.004), similarly to ES-SCLC. PCI in LCNEC showed an increase in mPFS (20.5 versus 6.4 months, p=0.09) and mOS (33.4 versus 8.6 months, p=0.05), as in ES-SCLC. Advanced LCNEC treated with SCLC first-line therapy has a similar clinical response and survival outcomes to ES-SCLC.http://openres.ersjournals.com/content/3/1/00128-2016.full |
| spellingShingle | Arsela Prelaj Sara Elena Rebuzzi Gabriella Del Bene Julio Rodrigo Giròn Berrìos Alessandra Emiliani Lucilla De Filippis Alessandra Anna Prete Silvia Pecorari Gaia Manna Carla Ferrara Daniele Rossini Flavia Longo Evaluation of the efficacy of cisplatin–etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC ERJ Open Research |
| title | Evaluation of the efficacy of cisplatin–etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC |
| title_full | Evaluation of the efficacy of cisplatin–etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC |
| title_fullStr | Evaluation of the efficacy of cisplatin–etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC |
| title_full_unstemmed | Evaluation of the efficacy of cisplatin–etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC |
| title_short | Evaluation of the efficacy of cisplatin–etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC |
| title_sort | evaluation of the efficacy of cisplatin etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in lcnec |
| url | http://openres.ersjournals.com/content/3/1/00128-2016.full |
| work_keys_str_mv | AT arselaprelaj evaluationoftheefficacyofcisplatinetoposideandtheroleofthoracicradiotherapyandprophylacticcranialirradiationinlcnec AT saraelenarebuzzi evaluationoftheefficacyofcisplatinetoposideandtheroleofthoracicradiotherapyandprophylacticcranialirradiationinlcnec AT gabrielladelbene evaluationoftheefficacyofcisplatinetoposideandtheroleofthoracicradiotherapyandprophylacticcranialirradiationinlcnec AT juliorodrigogironberrios evaluationoftheefficacyofcisplatinetoposideandtheroleofthoracicradiotherapyandprophylacticcranialirradiationinlcnec AT alessandraemiliani evaluationoftheefficacyofcisplatinetoposideandtheroleofthoracicradiotherapyandprophylacticcranialirradiationinlcnec AT lucilladefilippis evaluationoftheefficacyofcisplatinetoposideandtheroleofthoracicradiotherapyandprophylacticcranialirradiationinlcnec AT alessandraannaprete evaluationoftheefficacyofcisplatinetoposideandtheroleofthoracicradiotherapyandprophylacticcranialirradiationinlcnec AT silviapecorari evaluationoftheefficacyofcisplatinetoposideandtheroleofthoracicradiotherapyandprophylacticcranialirradiationinlcnec AT gaiamanna evaluationoftheefficacyofcisplatinetoposideandtheroleofthoracicradiotherapyandprophylacticcranialirradiationinlcnec AT carlaferrara evaluationoftheefficacyofcisplatinetoposideandtheroleofthoracicradiotherapyandprophylacticcranialirradiationinlcnec AT danielerossini evaluationoftheefficacyofcisplatinetoposideandtheroleofthoracicradiotherapyandprophylacticcranialirradiationinlcnec AT flavialongo evaluationoftheefficacyofcisplatinetoposideandtheroleofthoracicradiotherapyandprophylacticcranialirradiationinlcnec |